site background
Skip to content
Ivy Brain Tumor Center
Trial EligibilityDonate
Main Menu
  • Physicians
  • Industry
  • Ivy Blog
Talk to an Ivy Navigator
  • The Challenge
    • Current Standard of Care
    • Conventional Clinical Trials
  • Phase 0 Clinical Trials
    • Current Clinical Trials
      • Sonodynamic Therapy in DIPG
      • AZD1390 For Recurrent Grade IV Glioma
      • Niraparib for Newly Diagnosed Glioblastoma
      • Sonodynamic Therapy in Recurrent High-Grade Glioma
      • Pamiparib for newly diagnosed or recurrent glioblastoma
      • Ly3214996 plus abemaciclib for glioblastoma
      • Infigratinib in Recurrent Glioblastoma Patients
      • RIBOCICLIB PLUS EVEROLIMUS FOR RECURRENT HIGH-GRADE GLIOMA
      • RIBOCICLIB FOR RECURRENT MENINGIOMA
      • RIBOCICLIB FOR RECURRENT GLIOBLASTOMA
    • What is a Phase 0 Trial?
    • Why Ivy Clinical Trials?
    • What We Treat
      • Gliomas
      • Brain Metastases
      • Meningiomas
      • Ependymomas
      • Craniopharyngiomas
      • Pineal-Region Tumors
  • Patients
    • Patient Stories
    • What to Expect
    • Planning Your Visit
      • Lodging
      • Transportation
    • Patient Support
    • FAQs
    • Share Your Story
  • Research
    • Scientific Cores
    • Laboratories
      • Mehta Laboratory
      • Tovmasyan Laboratory
      • Tien Laboratory
      • Mirzadeh Laboratory
    • Certifications
    • Preclinical Work
    • Industry Collaboration
    • Published Research
    • Ivy Center Seminar Series
  • About
    • Team
      • Administration
      • Business Operations
      • Clinical Operations
      • Communications
      • Preclinical and Translational Science
    • New Ivy Headquarters
    • It’s personal
    • Barrow Neurological Institute
    • The Ben and Catherine Ivy Foundation
    • Newsroom
    • Events
    • Donate
    • Careers
    • Contact Us
  • ESPAÑOL

Talk to an Ivy Navigator

602-406-8605

Newly Diagnosed Glioblastoma

Home » Newly Diagnosed Glioblastoma
PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
  • February 6, 2021
A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration...
Read More
Arial shot of the Ivy Brain Tumor Center
Ivy Brain Tumor Center
  • The Challenge
    • Current Standard of Care
    • Conventional Clinical Trials
  • Phase 0 Clinical Trials
    • Why Ivy Clinical Trials?
    • What We Treat
    • Current Clinical Trials
  • Patients
    • Patient Stories
    • What to Expect
    • Planning Your Visit
    • Patient Support
    • FAQs
  • About
    • Team
    • Barrow Neurological Institute
    • The Ben and Catherine Ivy Foundation
    • Newsroom
    • Events
    • Donate
    • Careers
    • Contact Us

Stay Updated

Follow Us

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube

2910 North Third Avenue
Phoenix, Arizona 85013
(602) 406-6489
[email protected]
Mailing Address for Donations »

© Ivy Brain Tumor Center, 2022. All Rights Reserved.
  • Privacy Policy
  • Site Map
Important Notice

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device.